entertainment -WSS

entertainment

author：fashion 2025-09-29 21:13:20 - browse：136

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Senate panel clears PBM, hopsital reforms

WSS

HPV cancer vaccine study demonstrates efficacy

Victims of gun violence feel impacts long after bullet wound

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

STAT Executive Editor Rick Berke on STAT's 8th birthday

A clever new way to fix Medicaid and graduate medical education

Medicare will require more price transparency from hospitals

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

Biotech incubator Curie.Bio graduates its first startup

Hollywood unions extend contract negotiations for actors

Victims of gun violence feel impacts long after bullet wound

Wildfire smoke exposes gaps in outdoor worker protections

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Drug repurposing or repositioning? The language matters

The drug industry sees a key ally in the Senate prevail

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

knowledge

Excited delirium, Elijah McClain, and emergency physicians

TytoCare raises $49 million to build out AI

Influencer to be charged after chaos erupts in New York City's Union Square

ProMED, early warning system on disease outbreaks, in peril

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Sanofi CEO defends move to abandon profit guidance, boost research

hotspot

focus

entertainment

leisure time